tumorigenesis, progression and prognosis. Murine mesothelioma AB12 and RN5 cells treated with either chemotherapy or g-ray irradiation in culture, were used to compare gene expression profiles. The selected genes were confirmed by real-time PCR, flow cytometry and immunostaining. In vivo models, peritoneal lavage was collected at different time points after RN5 cell injection, to perform magnetic ranking cytometry with antibody-nanoparticle conjugates, and microarray assay. The expression of Tnfsf18 and Ngfr (CD271) genes associated with prognosis was evaluated in tumor tissues from MPM patients treated with SMART vs pre-SMART protocols, as SMART protocol has already shown significant clinical benefit. Image analysis was performed using Apero Imagescope program. Result: The proportion of MSC significantly increased after RN5 parental cells were treated with either chemotherapy, or g-ray irradiation, or in combination, while MSC showed more resistance to the above treatments, suggesting that chemoradiation resulted in MSC enrichment. Upregulation of genes Tnfsf18, Serpinb9b, Ly6a (Sca-1), Ngf, and Nppb were confirmed. CD271, the receptor of NGF, was shown to be upregulated after chemoradiation, especially after g-ray radiation with a dose of 10Gy. Mesothelial precursors captured with magnetic nanoparticles conjugated to anti-Msln and trapped in the microfluidic device in the presence of a magnetic field showed an increase over time from 2-8weeks. Image analysis of human section slides indicated that total positive area of CD271 staining was significantly lower in those who were treated with SMART protocol than those with pre-SMART protocol (p<0.0025). Similar results were obtained in the high, medium and low positive areas from the SMART group, and p values are 0.0013, 0.0017 and 0.0035, respectively, when compared with the pre-SMART group. Conclusion: MSC-specific genes like CD271 and Tnfsf18 might be used as potential prognostic indicators and therapeutic targets.
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(3), FLT1 (3), BAP1 (2), EGFR (2), FAT2 (2), FGFR4 (2), KIT (2), MAP3K1
(2), MLL4 (2), STK11 (2), APC, ATR, BRAF, BRCA2, CDKN2A, ERBB3, FBXW7, MET, KRAS, PIK3CA and so on. Among these mutations, 5 of NF2 mutations and 2 of NF1 mutations were loss-of-function mutations, which suggests the possible sensitivity of mTOR inhibitors administration. Besides, patients with the active or inactive mutations of KRAS, BRAF, CDKN2A, ERBB3, MET and PIK3CA gene might be sensitive to corresponding targeted drugs. MET exon 14 skipping mutation, commonly identified in non-small-cell cancer (NSCLC) patients, had never been reported in MM patients before. c-Met inhibitors such as crizotinib and cabozantinib may be of efficacy for this patient. Apart from predicting therapeutic effectiveness of MEK inhibitors, the detection of KRAS activating mutation may also provide prognostic information. Conclusion: NGS can identify genetic mutations comprehensively and provide predictive and prognostic implications for MM patients. It is a cost-effective tool to describe the genetic landscape of MM, which will facilitate the development of novel therapeutics for the treatment of MM patients. , another inhibitory T cell checkpoint protein, to be frequently expressed in MPMs. In search of other immunotherapeutic targets in MPM, we evaluated the expression of VISTA, its relationship with expression of PD-L1, and the association with response to PD-1 blockade in MPM. Method: We retrospectively interrogated the MPM database at Memorial Sloan Kettering to identify patients who received immune checkpoint inhibitors (ICIs). Archival tissue, where available, was obtained and we performed immunohistochemistry (IHC) using antibodies to PD-L1 (clone E1L3N) and VISTA (clone D1L2G), both from Cell Signaling Technology. Imaging studies were reviewed with a thoracic radiologist according to the modified RECIST criteria. Result: 37 patients were identified as having received at least one dose of ICI, of whom 26 patients had tissue for VISTA/PD-L1 testing. VISTA was positive (1%) in 25 (96%) and 50% in 22 (84%). PD-L1 was positive in 11 (42%) and 50% in two (8%). No evident correlation between VISTA and PD-L1 expression was seen. Correlation with response will be reported. Conclusion: In contrast to PD-L1, VISTA is highly expressed in most patients with MPM. Its expression appears independent of PD-L1 expression. Molecules targeting VISTA and its ligand should be prioritized for clinical development in MPM. Keywords: VISTA, Mesothelioma, Immunotherapy P2.06-41 Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC
